Cell Reprogramming-based Therapies for Diabetes

As a leader in the field of cell reprogramming, Creative Bioarray is committed to generating beta cells or islet tissue from iPSCs to help our clients perform basic pancreatic research and develop novel cellular therapies for type 1 diabetes (T1D). Our advanced iPSC technologies will accelerate the development of drugs for treating diabetes.


T1D is an autoimmune disease characterized by hyperglycemia as a result of absolute insulin deficiency. Current therapy for T1D relies on exogenous insulin supplementation, but this therapy is hard to obtain physiological control of blood glucose levels and is accompanied by long-term complications that adversely affect the patient's body. Transplantation of pancreatic beta cells as islet tissue or the whole pancreas has been shown to be an alternative treatment for T1D. Currently, hiPSCs are considered to be an attractive source of pancreatic β cells and islet-like organs.

Recently, several reports have proposed that iPSC-derived functionally mature β-like cells show glucose-responsive insulin-secreting capacity and that evaluation of animal models of diabetes showed that transplantation of these cells ameliorated hyperglycemia in diabetic mice. In addition, multiple research teams have focused on the research of transplantation methods, including immunoprotective devices that prevent host immune responses to implanted pancreatic cells, to develop regenerative therapies for diabetes.

Fig 1. Schematic of fabrication processes for islet-like organoids.Fig.1 Schematic of fabrication processes for islet-like organoids. (Shahjalal, 2018)

Development of New Therapies for Diabetes based on Cell Reprogramming

Cell Reprogramming-based Therapies for Diabetes

Researchers at Creative Bioarray are committed to applying iPSC technology to the development of new therapies for diabetes, and our excellent disease modeling capabilities allow validation of the therapeutic efficacy and safety of experimental diabetes therapies. We offer our clients the following strategies:

  • Generation of iPSC-derived beta cells for developing new therapies for diabetes.
  • Generation of the whole pancreas by blastocyst complementation for developing new therapies for diabetes. Blastocyst complementation is an attractive strategy for generating functional pancreatic tissue from iPSCs. To avoid other unwanted organs in chimeric animals generated from injected iPSCs, iPSCs induced into the target organ lineage are used to prevent differentiation into non-targeted cell types in chimeric animals.
  • Developing transplantation methods, including methods to induce direct implantation of pancreatic tissue into patients, and implantation of devices containing pancreatic tissue such as pancreatic cells encapsulated by bioengineered devices including semipermeable membranes.


  • High-quality service and fast turnaround time
  • Advanced technology platform
  • Wide range of cell reprogramming services
  • Comprehensive experimental data analysis system available
  • One-stop service

With our many years of service experience in the field of cell reprogramming, we provide our clients with expert technical support and scientific experimental strategies for the application of cell reprogramming technologies to develop new therapies for diabetes. If you are interested in our technology platform, please contact us for more details.


  1. Shahjalal, H.M.; et al. Generation of pancreatic β cells for treatment of diabetes: advances and challenges. Stem cell research & therapy. 2018, 9(1): 1-19.
For Research Use Only. Not For Clinical Use.